Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation

Kühlkamp, Volker; Schirdewan, Alexander; Stangl, Karl; Homberg, Michael; Ploch, Matthias; Beck, Olof

doi:10.1016/s0735-1097(00)00693-8

Cited by 236 publications

(139 citation statements)

References 40 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…A study investigated the effect on rhythm control in persistent AF patients who underwent electrical defibrillation using metoprolol, a β 1 -blocker similar to bisoprolol. 21) The results revealed that administration of metoprolol was effective in preventing AF recurrence. There are two reports comparing the suppressive effect of a β-blocker with that of an antiarrhythmic drug in P-AF patients.…”

Section: Discussionmentioning

confidence: 97%

Antiarrhythmic Effect of Bisoprolol, a Highly Selective .BETA.1-Blocker, in Patients With Paroxysmal Atrial Fibrillation

et al. 2008

View full text Add to dashboard Cite

SUMMARYIn the treatment of arrhythmia, β-blockers are mainly used to regulate the heart rate. However, β-blockers are also known as drugs with an antiarrhythmic effect due to the suppression of sympathetic activity. We evaluated the antiarrhythmic effects of a highly selective β 1 -blocker, bisoprolol, in patients with diurnal paroxysmal atrial fibrillation (P-AF).A total of 136 patients with symptomatic diurnal P-AF were enrolled. Patients were divided into a diurnal-specific P-AF group and a diurnal & nocturnal P-AF group, as well as into a bisoprolol single use group and a combined use group with an antiarrhythmic drug. The effects of bisoprolol were evaluated in 3 categories: subjective symptom improvement, quality of life (QOL) improvement, and elimination of P-AF episode in Holter electrocardiograms (ECGs). For patients with effective treatment, a long-term effect up to 24 months was evaluated.Five patients (3.7%) discontinued bisoprolol due to side effects. Following administration of bisoprolol, 109 patients (80%) experienced subjective symptom improvement, 103 patients (76%) experienced QOL improvement, and elimination of P-AF episodes in ECGs was observed in 84 patients (62%). The elimination rate of P-AF episodes in ECGs was higher in the diurnal P-AF group than in the diurnal & nocturnal P-AF group (P = 0.042). There was no significant difference between the bisoprolol single use group and the combined use group. A long-term suppressive effect by bisoprolol was observed in 70 of 83 patients (84%).The results demonstrate that bisoprolol has an antiarrhythmic effect against sympathetic diurnal P-AF, improving subjective symptoms and QOL and eliminating P-AF episodes in ECGs. (Int Heart J 2008; 49: 281-293)

show abstract

Section: Discussionmentioning

confidence: 97%

Antiarrhythmic Effect of Bisoprolol, a Highly Selective .BETA.1-Blocker, in Patients With Paroxysmal Atrial Fibrillation

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Donoszono również, że beta-adrenolityki ograniczają występowanie objawowych nawrotów AF [580,636,688], ale ta obserwacja może wynikać z korzystnego wpływu kontroli częstości rytmu komór, która powoduje, że AF częściej staje się bezobjawowe.…”

Section: Antyarytmiczne Działanie Leków Nieantyarytmicznychunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,401

4,206

View full text Add to dashboard Cite

“…248,249,687 Compared with placebo, beta-blockers are associated with a reduced risk of new-onset AF in patients with HFrEF and sinus rhythm. 23 Beta-blockers have also been reported to reduce symptomatic AF recurrences, 580,636,688 but this finding may be driven by the beneficial effect of rate control, which will render AF more often asymptomatic.…”

Section: Antiarrhythmic Effects Of Non-antiarrhythmic Drugsmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof¹,

Benussi²,

Kotecha³

et al. 2016

Eur J Cardiothorac Surg

930

625

View full text Add to dashboard Cite

Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation

Abstract: The results of this double-blind, placebo-controlled study in patients after cardioversion of persistent atrial fibrillation showed that metoprolol CR/XL was effective in preventing relapse into atrial fibrillation or flutter.

Cited by 236 publications

References 40 publications

Antiarrhythmic Effect of Bisoprolol, a Highly Selective .BETA.1-Blocker, in Patients With Paroxysmal Atrial Fibrillation

Antiarrhythmic Effect of Bisoprolol, a Highly Selective .BETA.1-Blocker, in Patients With Paroxysmal Atrial Fibrillation

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Contact Info

Product

Resources

About